TD Cowen Downgrades Terns Pharmaceuticals (TERN) to Hold

March 25, 2026 4:09 PM

TD Cowen analyst Ritu Baral downgraded Terns Pharmaceuticals (NASDAQ: TERN) from Buy to Hold with a price target of $53.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found